Displaying 1 - 23 of 23
Mellgard, G., Gilligan, M., Cliff, E. R. S., Bhutani, D., Mohyuddin, G. R., Eisenberger, A., Lentzsch, S., & Chakraborty, R. (2024). Risk stratification models overestimate progression risk in contemporary patients with smoldering multiple myeloma. HemaSphere, 8(3). Portico. https://doi.org/10.1002/hem3.61
Publication Date
Columbia Affiliation
Lamanna, N., Tam, C., Jurczak, W., Kontos, A., Konig, H., Ruppert, A. S., & Tsai, D. E. (2023). P1088: COMPARISON OF BLEEDING-RELATED EVENTS IN PATIENTS WHO RECEIVED PIRTOBRUTINIB WITH AND WITHOUT ANTITHROMBOTIC AGENTS. HemaSphere, 7(S3), e724362f. https://doi.org/10.1097/01.hs9.0000971248.72436.2f
Publication Date
Columbia Affiliation
View
Mehta-Shah, N., Jacobsen, E., Luigi Zinzani, P., Zain, J., Mead, M., Casulo, C., Gritti, G., Pinter-Brown, L., Izutsu, K., Waters, S., Brammer, J., Pro, B., & Horwitz, S. (2023). P1124: DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA FROM THE PHASE 2 PRIMO TRIAL EXPANSION PHASE: OUTCOMES BY BASELINE HISTOLOGY. HemaSphere, 7(S3), e3891642. https://doi.org/10.1097/01.hs9.0000971392.38916.42
Publication Date
Columbia Affiliation
View
Brown, J. R., Eichhorst, B., Ghia, P., Jurczak, W., Kahl, B., Lamanna, N., Robak, T., Shadman, M., Tam, C., Qiu, L., Cohen, A., Zhang, M., Salmi, T., Paik, J., Wang, L., Zhang, J., MA, H., & Tedeschi, A. (2023). P631: CHARACTERIZATION OF ZANUBRUTINIB SAFETY/TOLERABILITY PROFILE AND COMPARISON WITH IBRUTINIB PROFILE IN PATIENTS WITH B-CELL MALIGNANCIES: POST HOC ANALYSIS OF A LARGE CLINICAL TRIAL SAFETY DATABASE. HemaSphere, 7(S3), e356884b. https://doi.org/10.1097/01.hs9.0000969428.35688.4b
Publication Date
Columbia Affiliation
View
Eichhorst, B., Lamanna, N., O’brien, S., Tam, C., Qiu, L., Yang, K., Wu, K., Salmi, T., Barnes, G., & Brown, J. R. (2023). P640: ZANUBRUTINIB VS IBRUTINIB IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA (R/R CLL/SLL): IMPACT ON HEALTH-RELATED QUALITY OF LIFE (HRQOL). HemaSphere, 7(S3), e02428b9. https://doi.org/10.1097/01.hs9.0000969464.02428.b9
Publication Date
Columbia Affiliation
View
Hijiya, N., Kapoor, S., Hoch, M., Descamps, L., Dasgupta, K., & Cardoso, A. P. T. (2023). PB1980: ASC4KIDS: A MULTICENTER, OPEN-LABEL, PHASE 1B/2 STUDY TO DETERMINE THE DOSE AND SAFETY OF ASCIMINIB IN PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE. HemaSphere, 7(S3), e1669755. https://doi.org/10.1097/01.hs9.0000974736.16697.55
Publication Date
Columbia Affiliation
View
Lee, H. C., Bumma, N., Richter, J., Dhodapkar, M., Hoffman, J. E., Suvannasankha, A., Zonder, J., Shah, M. R., Lentzsch, S., Maly, J. J., Ye, J. C., Wu, K. L., Deveaux, M., Chokshi, D., Boyapati, A., Hazra, A., Lorenc, K. R., Kroog, G., Houvras, Y., & Jagannath, S. (2023). S197: LINKER-MM1 STUDY: LINVOSELTAMAB (REGN5458) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA. HemaSphere, 7(S3), e1610068. https://doi.org/10.1097/01.hs9.0000967700.16100.68
Publication Date
Columbia Affiliation
View
Kater, A., Harrup, R., Kipps, T. J., Eichhorst, B., Owen, C. J., Assouline, S., Lamanna, N., Robak, T., de la Serna, J., Jaeger, U., Cartron, G., Montillo, M., Mellink, C., Chyla, B., Thadani-Mulero, M., Lefebure, M., Jiang, Y., Millen, R., Boyer, M., & Seymour, J. F. (2023). S201: FINAL 7-YEAR FOLLOW UP AND RETREATMENT SUBSTUDY ANALYSIS OF MURANO: VENETOCLAX-RITUXIMAB (VENR)-TREATED PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL). HemaSphere, 7(S3), e492813f. https://doi.org/10.1097/01.hs9.0000967716.49281.3f
Publication Date
Columbia Affiliation
View
Hanna, R., Frangoul, H., Mckinney, C., Pineiro, L., Mapara, M., Chang, K.-H., Jaskolka, M., Kim, K., Rizk, M., Afonja, O., Lawal, A., & Walters, M. (2023). S264: EDIT-301 SHOWS PROMISING PRELIMINARY SAFETY AND EFFICACY RESULTS IN THE PHASE I/II CLINICAL TRIAL (RUBY) OF PATIENTS WITH SEVERE SICKLE CELL DISEASE USING HIGHLY SPECIFIC AND EFFICIENT ASCAS12A ENZYME. HemaSphere, 7(S3), e05170e0. https://doi.org/10.1097/01.hs9.0000967968.05170.e0
Publication Date
Columbia Affiliation
View
Locatelli, F., Lang, P., Corbacioglu, S., LI, A., De La Fuente, J., Wall, D., Meisel, R., Shah, A. J., Liem, R., Mapara, M., Carpenter, B., Kwiatkowski, J., Domenica Cappellini, M., Kattamis, A., Sheth, S., Grupp, S., Kohli, P., Shi, D., Ross, L., … Frangoul, H. (2023). S270: TRANSFUSION INDEPENDENCE AFTER EXAGAMGLOGENE AUTOTEMCEL IN PATIENTS WITH TRANSFUSION-DEPENDENT ΒETA-THALASSEMIA. HemaSphere, 7(S3), e8473180. https://doi.org/10.1097/01.hs9.0000967992.84731.80
Publication Date
Columbia Affiliation
View
Flerlage, J. E., Birz, S., Castellino, S. M., Appel, B., Furner, B., Graglia, L., Henderson, T. O., Hodgson, D., Hoppe, B. S., Kahn, J., Keller, F. G., Kessel, S., Li, C., Li, M., Lucas, J., Mccarten, K., Metzger, M., Milgrom, S., Parsons, S. K., … Kelly, K. M. (2022). P086: Advancing Pediatric Hodgkin Lymphoma Research Through NODAL. HemaSphere, 6, 39–40. https://doi.org/10.1097/01.hs9.0000890912.56229.80
Publication Date
Columbia Affiliation
View
P., B., R., I., R., O., D., M., E., M., P., K., N., G., & A., B. (2022). O-08: NEUROCOGNITIVE IMPAIRMENT IN UGANDAN CHILDREN WITH SICKLE CELL ANEMIA COMPARED TO NON-SICKLE SIBLINGS. HemaSphere, 6, 05–06. https://doi.org/10.1097/01.hs9.0000872840.49305.3f
Publication Date
Columbia Affiliation
View
Tremblay, D., Srisuwananukorn, A., Ronner, L., Podoltsev, N., Gotlib, J., Heaney, M. L., Kuykendall, A., O’Connell, C. L., Shammo, J. M., Fleischman, A., Mesa, R., Yacoub, A., Hoffman, R., Moshier, E., Zubizarreta, N., & Mascarenhas, J. (2022). European LeukemiaNet Response Predicts Disease Progression but Not Thrombosis in Polycythemia Vera. HemaSphere, 6(6), e721. https://doi.org/10.1097/hs9.0000000000000721
Publication Date
Columbia Affiliation
DeAngelo, D. J., Pullarkat, V., Piris-Villaespesa, M., George, T. I., Patel, J. L., Ustun, C., Bose, P., Heaney, M. L., Pilla, A., Massaro, M., Exter, B., Jolin, H. A., Mikhak, Z., & Tashi, T. (2022). P1049: A Phase 2 Study of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent Kit D816V Inhibitor, in Adults With Advanced Systemic Mastocytosis (Apex): Methods, Baseline Data, and Early Insights. HemaSphere, 6, 939–940. https://doi.org/10.1097/01.hs9.0000847064.38588.9b
Publication Date
Columbia Affiliation
View
Eyre, T. A., Wang, M. L., Shah, N. N., Alencar, A. J., Gerson, J. N., Patel, M. R., Fakhri, B., Vandenberghe, E., Jurczak, W., Tan, X. N., Lewis, K. L., Fenske, T., Wang, Y., Coombs, C. C., Flinn, I., Lewis, D., Le Gouill, S., Gandhi, M., Chay, C., … Cheah, C. Y. (2022). P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY. HemaSphere, 6, 991–992. https://doi.org/10.1097/01.hs9.0000847272.47630.ff
Publication Date
Columbia Affiliation
View
Pemmaraju, N., Cuglievan, B., Lasky, J., Kheradpour, A., Hijiya, N., Stein, A. S., Meshinchi, S., Mullen, C., Angelucci, E., Vinti, L., Mughal, T. I., & Pawlowska, A. (2022). P521: TREATMENT OF BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM IN PEDIATRIC PATIENTS WITH TAGRAXOFUSP, A CD123-TARGETED THERAPY. HemaSphere, 6, 420–421. https://doi.org/10.1097/01.hs9.0000844972.31512.dd
Publication Date
Columbia Affiliation
View
Hillmen, P., Brown, J., Lamanna, N., O’Brien, S., Tam, C., Qiu, L., Yang, K., Barnes, G., Wu, K., Salmi, T., & Eichhorst, B. (2022). P663: HEALTH-RELATED QUALITY OF LIFE OUTCOMES ASSOCIATED WITH ZANUBRUTINIB VS IBRUTINIB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (RR) CLL/SLL: RESULTS FROM THE RANDOMIZED PHASE 3 ALPINE TRIAL. HemaSphere, 6, 561–562. https://doi.org/10.1097/01.hs9.0000845536.66920.d3
Publication Date
Columbia Affiliation
View
Hijiya, N., Kapoor, S., Hoch, M., Descamps, L., Bayar, M. A., & Ramscar, N. (2022). PB1903: TRIAL IN PROGRESS: A MULTICENTER, OPEN-LABEL, PHASE IB/II STUDY TO DETERMINE THE DOSE AND SAFETY OF ASCIMINIB IN PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP). HemaSphere, 6, 1782–1783. https://doi.org/10.1097/01.hs9.0000850464.45271.b3
Publication Date
View
Mato, A. R., Pagel, J. M., Coombs, C. C., Shah, N. N., Lamanna, N., Munir, T., Lech-Maranda, E., Eyre, T. A., Woyach, J. A., Wierda, W. G., Cheah, C. Y., Cohen, J. B., Roeker, L. E., Patel, M. R., Fakhri, B., Barve, M. A., Tam, C., Lewis, D., Gerson, J. N., … Jurczak, W. (2022). S147: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED CLL/SLL: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY. HemaSphere, 6, 48–49. https://doi.org/10.1097/01.hs9.0000843480.04890.cc
Publication Date
Columbia Affiliation
View
Sallman, D. A., Al Malki, M. M., Asch, A. S., Wang, E. S., Jurcic, J. G., Bradley, T. J., Flinn, I. W., Pollyea, D. A., Kambhampati, S. N., Tanaka, T. N., Zeidner, J. F., Garcia-Manero, G., Jeyakumar, D., Gu, L., Tan, A., Chao, M., O’Hear, C., Lal, I., Vyas, P., & Daver, N. (2022). S166: MAGROLIMAB IN COMBINATION WITH AZACITIDINE FOR PATIENTS WITH UNTREATED HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR MDS): 5F9005 PHASE 1B STUDY RESULTS. HemaSphere, 6, 67–68. https://doi.org/10.1097/01.hs9.0000843556.59348.1d
Publication Date
Columbia Affiliation
View
Zonder, J. A., Richter, J., Bumma, N., Brayer, J., Hoffman, J. E., Bensinger, W. I., Wu, K. L., Xu, L., Chokshi, D., Boyapati, A., Cronier, D., Houvras, Y., Rodriguez Lorenc, K., Kroog, G. S., Dhodapkar, M. V., Lentzsch, S., Cooper, D., & Jagannath, S. (2022). S189: EARLY, DEEP, AND DURABLE RESPONSES, AND LOW RATES OF CRS WITH REGN5458, A BCMAXCD3 BISPECIFIC ANTIBODY, IN A PHASE 1/2 FIRST-IN-HUMAN STUDY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA. HemaSphere, 6, 90–91. https://doi.org/10.1097/01.hs9.0000843648.44771.79
Publication Date
Columbia Affiliation
View
Prockop, S., Beitinjaneh, A., Choquet, S., Dahiya, S., Dinavahi, R., Farah, R., Gamelin, L., Ghobadi, A., Mehta, A., Nayak, P., Reshef, R., Satyanarayana, G., Stiff, P., Ye, W., & Mahadeo, K. M. (2022). S256: TABELECLEUCEL FOR EBV-DRIVEN POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL OR SOLID ORGAN TRANSPLANT AFTER FAILURE OF RITUXIMAB ± CHEMOTHERAPY (ALLELE). HemaSphere, 6, 157–158. https://doi.org/10.1097/01.hs9.0000843916.04522.0a
Publication Date
Columbia Affiliation
View
Houot, R., Poeschel, V., Altmann, B., Angel, S., Thurner, L., Illmer, T., Andre, M., Dreyling, M., Maisonneuve, H., Tilly, H., Mayer, S., Casasnovas, O., Le Gouill, S., Offner, F., Cartron, G., Kerkhoff, A., Weber, T., Hoffmann, J., Ziepert, M., … Held, G. (2022). Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma. HemaSphere, 6(2), e672. https://doi.org/10.1097/hs9.0000000000000672
Publication Date
Columbia Affiliation